The American Society of Gene and Cell Therapy (ASGCT) announced Jeffrey Chamberlain, PhD, endowed chair in Muscular Dystrophy, as the ASGCT vice president. Chamberlain will assume this role starting June 1, 2021, and will serve a three-year term. In 2022, he will serve as the president-elect and, in 2023, he will serve as the president.
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.